


Statement of Standalone Un-Audited Financial Results for the Quarter ended June 30, 2020

Sr. No.	Particulars	Quarter ended			Year ended	
		30-06-2020 31-03-2020		30-06-2019	31-03-2020	
		(Unaudited)	(Audited)	(Unaudited)	(Audited)	
1	Income	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	,			
	Revenue from Operations	602 39	1397 80	1432 49	5561 43	
	Other Income	0 47	8 55	0 24	9 26	
	Total Revenue	602.85	1406.35	1432.73	5570.69	
II	Expenses					
	(a) Cost of Materials Consumed	327 57	674 50	581 00	2455 26	
	(b) Purchases of Stock-in-Trade		8 22	28 80	37 02	
	(c) Changes in Inventories of Finished Goods, Work-in-Progress & Stock-					
	in-Trade	(273 21)	154.26	(6 55)	(63 32	
	(d) Employee Benefits Expense	224 07	299 34	256 98	1067 37	
	(e) Finance Costs	25 13	133 21	29 85	218 32	
	(f) Depreciation and Amortisation Expense	38 36	103 75	15 64	155 39	
	(g) Other Expenses	239 59	7 08	470 36	1485 15	
	Total expenses	581.51	1380.36	1376.08	5355.19	
10	Profit / (Loss) before Exceptional items and Tax (I - II)	21 34	25 99	56 65	215 50	
IV	Exceptional Items				(2)	
٧	Profit / (Loss) after Exceptional items and Tax (III-IV)	21 34	25 99	56 65	215 50	
VI	Tax Expense					
	(1) Current Tax	5 5 5	23 88	15 76	71 58	
	(2) Deferred tax				14 33	
	Total Tax Expenses	5.55	23.88	15.76	85.91	
VII	Profit / (Loss) for the period form Continuing Operations (V-VI)	15 79	2 11	40 89	129 59	
VIII	Profit / (Loss) from Discontinuing Operations			-	-	
IX	Tax expenses of Discontinuing Operations		-			
X	Profit / (Loss) From Discontinuing Operations (after tax) (VIII-IX)	-				
ΧI	Profit / (Loss) for the period (VII+X)	15 79	2 11	40 89	129 59	
XII	Other Comprehensive Income					
	A. (I) Items that will not be reclassified to profit or loss					
	(ii) Income tax relating to items that will not be reclassified to profit of		•	-		
	B. (I) Items that will be reclassified to profit or loss		-			
	(ii) Income tax relating to items that will be reclassified to profit or	-				
XIII	Total Comprehensive Income for the period	15 79	2 11	40 89	129 5	
XIV	Details of Equity share capital					
	Paid up Equity capital (Face Value of Rs 10/- each)	364 83	364 83	364 83	364 8	
	Face value of Equity Share Capital	10 00	10 00	10 00	100	
XV	Earnings Per Equity Share for Continuing operation:					
	(a) Basic	0 43	0 06	1 12	3 5	
	(b) Diluted	0 43	0 06	1 12	3 5	
XVI	Earnings Per equity share for Discontinuing operation					
	(a) Basic			7	2	
	(b) Diluted					
XVII	Earnings Per Equity Share for Discontinuing & Continuing operation :					
	(a) Basic	0.43	0.06	1 12	3 5	
	(b) Diluted	0.43	0 06	1 12	3.5	





Notes:

- 1). The above Statement of Standalone Unaudited Financial Results for the quarter ended 30th June, 2020 ("Statement') is prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended. The Statement is, as reviewed by the Audit Committee, considered and approved by the Board of Directors at its meeting held on 10th August, 2020. The Statement is subjected to 'limited review' by the Auditors of the Company and their report contains no qualification.
- 2). The Company has one reportable business segment "Medical Devices".
- 3). In accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, the Statutory Auditors have carried out a Limited Review of the Standalone Un-Audited Financial Results for the quarter ended 30th June, 2020.
- 4). The industry as a whole has been adversely impacted by the spread of COVID-19. The Company faces significant headwinds due to COVID-19 which have impacted the operations of the Company adversely starting from the month of March 2020 onwards particularly by way of closures due to complete lockdown. This unprecedented disruption has had an adverse impact on the quarterly performance and continue to impact the business and our financial results. In this crisis, our priorities are to protect our employees and their families from COVID-19 and the society associated with it. We do anticipate material risk to business prospects over the medium to long term. The Company has begun restoration of operations as permitted by the Government and Local / Regulatory authorities, with controlled movement, maintaining social distancing, taking appropriate hygiene measures and following the directions of regulatory authorities. The Company has evaluated impact on its business operations and financial position based on its review of current indicators of future economic conditions. The Company is closely monitoring the developments and possible effects that may result from the current pandemic on its financial condition, liquidity and operations and is actively working to minimize the impact of this unprecedented situation. As the situation is continuously evolving, the eventual impact may be different from the estimates made as of the date of approval of these Results.

5). The unaudited results for the Quarter ended June 30, 2020 are available on the website of BSE Limited at www.bseindia.com and on Company's website at www.centenialindia.com.

for

Place : Mumbai, Maharashtra Date : August 10, 2020

NTENIAL SURGICAL SUTURE LTD.

Vijay MAJREKAR Managing Director & Chief Executive Officer

DIN: 00804808